A B S T R A C T. The objective of this study was to determine the direct actions of nitroprusside and nitroglycerin on the pulmonary vascular bed in the intactchest dog. These widely used nitrogen oxide-containing vasodilator agents decreased pulmonary arterial pressure and increased cardiac output without altering left atrial pressure. Reductions in pulmonary arterial pressure and pulmonary vascular resistance were small under resting conditions, but were enhanced when pulmonary vascular tone was elevated by infusion of a stable prostaglandin analog that increases pulmonary vascular resistance by constricting intrapulmonary veins and upstream segments. In studies in which pulmonary blood flow to the left lower lobe was maintained constant, nitroprusside and nitroglycerin caused small but significant reductions in lobar arterial and small-vein pressures without significantly affecting left atrial pressure. With constant blood flow, lobar vascular pressures that were reduced in response to the vasodilators were more greatly reduced when lobar vascular resistance was increased by infusion of the prostaglandin analog or serotonin. However, when lobar vascular pressures were elevated by passive obstruction of lobar venous outflow, vasodilator responses to nitroprusside and nitroglycerin were not enhanced. These data suggest that nitroprusside and nitroglycerin decrease pulmonary vascular resistance by dilating intrapulmonary veins and upstream segments. These responses were minimal under control conditions but were enhanced when vascular tone was increased. This vasodilator action is independent of passive factors such as changes in pulmonary blood flow or left atrial pressure and is not secondary to an effect of these agents on the systemic circulation. Pulmonary vasodilator responses to nitroprusside and nitroglycerin were, however, found to be dependent on the existing level of vasomotor tone in the pulmonary vascular bed.
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INTRODUCTION
The major pharmacologic property of drugs belonging to the class of organic nitrates and other nitrogen oxide-containing agents such as nitroprusside is to relax vascular smooth muscle (1) . Nitroglycerin is a vasodilator agent that is widely used in the treatment of anginal disease whereas nitroprusside is used in the management of hypertensive emergencies and for afterload reduction in patients with left heart failure and myocardial infarction (1) (2) (3) (4) . Although the systemic vascular responses to nitroprusside and nitroglycerin have been intensively investigated (5) (6) (7) (8) , the actions of these substances on the pulmonary circulation have received less attention and little, if anything, is known about the effects of these agents on the pulmonary veins (9) (10) (11) (12) (13) . Nitroprusside and nitroglycerin have been reported to decrease pulmonary arterial pressure in patients with congestive heart failure (9) (10) (11) (12) . However, in those studies the vasodilator agents increased cardiac output and, when measured, decreased pulmonary arterial-wedge pressure so that the direct effects of these substances on the pulmonary vascular bed are uncertain (9) (10) (11) (12) . In a recently published study nitroprusside was reported to have no significant effect on pulmonary arterial pressure in the dog and the authors speculate that this vasodilator agent reduces pulmonary vascular distending pressure through its actions on the systemic circulation (13) . It was also reported in that study that nitroprusside altered the pressure-volume characteristics of the pulmonary circulation (13 (14) . The thermistor-tip catheter was positioned in the main pulmonary artery and the injectate, 5 ml of 0.9% NaCl at room temperature (22-24°C), was rapidly injected into the proximal port on the thermistor catheter. After all catheters were secured, the animals were heparinized 500 U/kg i.v., and were permitted to stabilize for 30 min before experiments were started. Cardiac output during the control period averaged 121 ml/kg per min and is in agreement with previous studies from this laboratory (15, 16) .
In the 20 animals in which blood flow to the left lower lobe was maintained constant, a specially designed 20F balloon perfusion catheter (U. S. Catheter and Instrument Co., Glen Falls, N. Y.) was positioned in the artery to the left lower lobe from the left external jugular vein under fluoroscopic guidance. A 2-mm Teflon catheter with end and side holes and with its tip positioned 1-2-cm distal to the balloon on the perfusion catheter was used to measure perfusion pressure in the lobar artery. In these experiments, catheters with end and side holes were passed into the aorta and into the left atrium transseptally. For measurement of small intrapulmonary vein pressures a 0.9-mm Teflon catheter with end and side holes near the tip was passed through a 3F Teflon catheter that previously had been wedged in a small intrapulmonary vein and this catheter was also wedged in yet a smaller vein. The 0.9-mm catheter was then withdrawn from the wedge position until pressure dropped from a wedge value which approximated lobar arterial pressure to smallvein pressure (8-11 mm Hg) and the pressure waveform followed the contour of the pressure waveform in the large vein. The 0.9-mm catheter was fixed in place by means of a Cope adaptor (Becton-Dickinson & Co.) after the 3F catheter had been withdrawn to the left atrium. The procedure for measurement of small intrapulmonary vein pressures has been described (17, 18) . After all catheters were positioned and the animals heparinized, 1,000 U/kg i.v., the balloon on the perfusion catheter was gradually distended with 2-4 ml of contrast media (Hypaque, sodium diatrizoate, 50%, Winthrop Labs, Evanston, Ill.) until lobar arterial and small-vein pressures decreased to near left atrial pressure. The vascularly isolated left lower lobe was then autoperfused with blood withdrawn by way of a 12F withdrawal catheter passed into the right atrium from a femoral vein. The lobe was perfused by means of a roller pump (model 3500, Sarns, Inc., Ann Arbor, Mich.) and the pumping rate was adjusted so that mean pressures in the lobar artery and main pulmonary artery were similar. The pumping rate was 293±12 ml/min (mean± SE, n = 20) 30 , 100, and 300 Ag. All doses were administered in a random order and enough time was permitted between injections for hemodynamic variables to return to base-line levels. Nitroprusside and nitroglycerin were infused intravenously with an infusion pump model 945 (Harvard Apparatus Co., S. Natick, Mass.). Responses to nitroprusside and nitroglycerin were obtained in the control period and when pulmonary vascular resistance was elevated by intravenous infusion of a stable prostaglandin-endoperoxide analog (15S)hydroxyl-1 la,9a(epoxymethano)prosta-5Z,13E dienoic acid (Upjohn Co., Kalamazoo, Mich.). The analog was dissolved in 100% ethanol at a concentration of 5 mg/ml and working solutions were prepared on a weekly basis. The analog was infused with a Harvard pump at rates that increased pulmonary vascular resistance by -100% and were 0.5-20,ug/min. The elevations in pulmonary arterial pressure were well maintained during infusion of the analog and this substance had little, if any, effect on systemic arterial pressure or on cardiac output, and responses to this substance were independent of interaction with formed elements or platelet aggregation (16) . In experiments in which responses to nitroprusside and nitroglycerin were investigated in the left lower lobe, these agents were injectecl directly into the perfused lobar artery in doses of 10-300 Ag in a random manner or were infused into the lobar artery at rates of 60-180,g/min. Responses were investigated under baseline conditions and when lobar vascular resistance was elevated by intralobar infusion of the prostaglandin-endoperoxide analog at rates of 0.25-8 ,ug/min or elevated by serotonin creatinine sulfate (Sigma Chemiical Co., St. Louis, Mo.) at 62-240 jug/miin.
All hemodynamic data are expressed as mean±SE. In experiments in which pulmonary blood flow was not controlled with a pump, cardiac output was measured at the maximum reductions in pulmonary arterial and aortic pressures. Pulmonary vascular resistance expressed in millimeters of mercury per liter per minute was calculated by dividing mean pulmonary arterial pressure minus mean left atrial pressure by the cardiac output. Systemic vascular resistance in the same units was calculated by dividing mean aortic pressure minus mean right atrial pressure by the cardiac output. The data were analyzed by the methods by Snedecor and Cochran (19) for paired or group comparison. A P value of <0.05 was used as the criterion for statistical significance.
RESULTS
Cardiopulmonary responses to nitroprusside and nitroglycerin. Cardiopulmonary responses to nitroprusside and nitroglycerin were investigated in the anesthetized dog under base-line conditions and when pulmonary vascular resistance was elevated by infusion of the stable prostaglandin-endoperoxide analog. Under basal conditions intravenous injections of nitroprusside and nitroglycerin in doses of 100 and 300 ,ug produced small but statistically significant reductions in mean pulmonary arterial pressure, whereas mean left atrial pressure was unchanged. Cardiac output measured at the maximum fall in pulmonary arterial pressure was increased (Table I) . Nitroprusside and nitroglycerin injections also decreased mean systemic arterial pressure without causing any significant effect on mean right atrial pressure (Table II) . The fall in systemic arterial pressure preceded the decrease in pulmonary arterial pressure and cardiac output measured at the maximum fall in systemic arterial pressure was increased significantly (Table II) (Table III) . Cardiac output increased whereas pulmonary and systemic vascular resistances decreased and all values returned to control level 5 min after the infusions were discontinued (Table III) . The maximum reductions in pulmonary arterial pressure and pulmonary vascular resistance in response to intravenous infusions of nitroprusside and nitroglycerin were significantly greater when pulmonary vascular resistance was elevated by infusion of the prostaglandin analog (Tables III and IV) .
Responses to nitroprusside and nitroglycerin in the perfused lobe. Since nitroprusside and nitroglycerin decreased ptulmonary arterial pressure and increased pulmonary blood flow, the effects of these substances NITROGLYCERN (Table V) . Lobar arterial and smallvein pressures returned to control values after infusions of the vasodilator agents and the prostaglandin analog were discontinued (Table V) .
In another series of experiments in which blood flow to lobe was maintained constant, responses to nitroprusside and nitroglycerin were compared when lobar vascular resistance was at basal levels and when tone was increased by intralobar infusion ofserotonin. Injections of the vasodilator agents into the lobar artery caused small reductions in lobar arterial pressure under base-line conditions which were significant at the 300 ,ug dose for nitroprusside and the 30 and 100 ,ug doses for nitroglycerin (Table VI) . Intralobar infusion of serotonin 60-240 ,ug/min increased lobar arterial pressure FIGURE 4 Comparative reductions in lobar arterial and small vein-pressures in response to intralobar injections of 10-100 gg nitroglycerin in the control period (A) and when lobar vascular tone was elevated by intralobar infusion ofthe prostaglandin-endoperoxide analog (B). Decreases in lobar arterial and venous pressures in response to 10-100 ,g nitroglycerin were significant during the control period. Decreases in lobar arterial and small-vein pressures were significantly greater at doses of 10, 30, and 100 gg when tone was elevated than the pooled values at 10-100 ,pg during the control period. n (number of animals) = 11. U, lobar artery; H, lobar vein.
without altering left atrial pressure (Table VI) . When lobar vascular resistance was increased by infusion of serotonin, reductions in lobar arterial pressure in response to intralobar injections of nitroprusside and nitroglycerin were greatly enhanced (Table VI) .
Lobar responses to nitroprusside and nitroglycerin when lobar vascular pressures were increased passively. Lobar vascular responses to nitroprusside and nitroglycerin were also investigated when lobar arterial and small-vein pressures were elevated by partial obstruction of lobar venous outflow by means of a balloon catheter in the vein draining the left lower lobe. Under base-line conditions there was no significant pressure gradient across the balloon in the lobar vein and intralobar injections of 300 ,ug nitroprusside and 100 ,ug nitroglycerin caused small statistically significant reductions in lobar arterial and small-vein pressures (Fig. 5, upper panel) . The balloon was then slowly distended with contrast medium until mean pressures in the lobar artery and small vein were elevated to approximately the same levels as observed during intrapulmonary infusion of the prostaglandin analog (Table  VII) . Balloon distension increased mean lobar arterial and small vein pressures without affecting mean left 898 P. J. Kadowitz atrial or aortic pressure (Table VII) . The elevations in lobar arterial and venous pressures were well maintained during the period of balloon distension and the lobar arterial to small-vein pressure gradient decreased (Fig. 5 ).
DISCUSSION
Results of the present study in the dog show that nitroprusside and nitroglycerin decrease pulmonary and systemic arterial pressures. The reduction in pulmo- Although vasodilator responses to nitroprusside and nitroglycerin were enhanced when pulmonary vasomotor tone was increased by an active process, responses to these agents were not enhanced when lobar vascular pressures were passively elevated by partially obstructing lobar venous outflow. These data suggest that reductions in pulmonary arterial pressure in response to nitroprusside in patients with congestive heart failure may, for the most part, be passive in nature and may be secondary to the improvement in left ventricular function which results in reductions in left ventricular end-diastolic and left atrial pressures (4, (9) (10) (11) (12) . The passive nature of the pulmonary response to nitroprusside was observed in a recently published study in which this agent produced similar decreases in mean pulmonary arterial (11.7±1.5 mm Hg) and mean pulmonary arterial-wedge pressures (11.0±1.5 mm Hg) in patients with congestive heart failure (12) . The present data with passive increases in pulmonary vascular pressures are also consistent with a recently published study in the dog in which nitroprusside had little if any effect on pulmonary arterial pressure when intravascular volume was expanded by infusion of 2-3 Liters of saline or when autologous blood was transfused (13) . However, the present study extends the results of previous studies by showing that nitroprusside and nitroglycerin have marked vasodilator activity in the pulmonary vascular bed when pulmonary vascular resistance is increased by an active process. In addition, our study shows that vasodilator responses to these agents are not related to changes in pulmonary blood flow or left atrial pressure since responses could be demonstrated in experiments in which blood flow was constant and left atrial pressure did not change.
In experiments in which pulmonary blood flow was not controlled, the decrease in pulmonary arterial pressure followed the fall in systemic arterial pressure indicating that pulmonary vascular responses to nitroprusside and nitroglycerin may be secondary to changes in the systemic circulation, as was recently suggested (13) . However, the present experiments in the perfused lobe indicate that responses to nitroprusside or nitroglycerin were not secondary to their actions on the systemic circulation, because marked vasodilator responses could be elicited under enhanced tone conditions when these agents were injected directly through the artery to the lobe at lower doses that had no significant effect on left atrial or systemic arterial pressure. Moreover, when injected into the perfused lobar artery in larger doses that decreased systemic arterial pressure, lobar vasodilator response preceded the fall in systemic arterial pressure. These data suggest that nitroprusside and nitroglycerin dilate the pulmonary vascular bed by a direct action on pulmonary vascular smooth muscle. Although the mechanism by which vasodilator agents, like nitroprusside or nitroglycerin, relax vascular smooth muscle is uncertain, earlier studies have suggested that critical sulffiydryl groups may be required for the vasodilator effects of nitrites (21, 22) . Recent studies in our laboratory have demonstrated that nitroprusside, nitroglycerin, sodium nitrite, and nitric oxide relax coronary arterial smooth muscle and activate soluble guanylate cyclase from the same tissue (23, 24) . This activation may be due to release of a reactive nitrogen oxide group which results in the elevation of cyclic GMP levels that correlate closely with the smooth muscle relaxation (25) . In support of a mechanism involving cyclic GMP, lipophilic analogs of this nucleotide have been shown to relax vascular smooth muscle (26) . Preliminary studies from this laboratory indicate that nitroprusside and nitroglycerin activate guanylate cyclase from intrapulmonary vessels.' It is, therefore, possible that these substances dilate pulmonary vessels by elevating cyclic GMP levels in smooth muscle in these vessels.
There has been increased clinical interest in the use of vasodilator agents in the management of cor pulmonale and pulmonary hypertension (27) (28) (29) . It has been reported that diverse agents such as hydralazine, isoproterenol, diazoxide, tolazoline, and phentolamine may be useful in the treatment of pulmonary hypertension (27) (28) (29) (30) (31) . It has also been shown that prostacyclin and several prostacyclin-like substances have good vasodilator activity in the pulmonary vascular bed (15, (32) (33) (34) and it has recently been reported that prostacyclin produced a marked reduction in pulmonary arterial pressure in a patient with severe idiopathic pulmonary hypertension (35) . The use of nitroglycerin in the treatnent of angina, and nitroprusside in the treatment of hypertensive emergencies and congestive heart failure, is well established (1-4) . The present studies suggest that nitroprusside and nitroglycerin are also capable of reducing pulmonary arterial pressure when pulmonary vascular resistance is increased by an active process. In addition, the present data indicate that the nitrogen oxide-containing agents are capable of reducing small-vein pressures. These data suggest that nitroprusside or nitroglycerin may decrease capillary pressure in the lung when pressures in the small veins are increased by an active process. Although the nitrogen oxide-containing agents are capable of reducing afterload on the right side, they also are capable of dilating vessels in poorly ventilated areas of the lung, which may result in a secondary hypoxemia. Therefore, these agents must be used with caution in the management ofdiseases such as idiopathic pulmonary hypertension, cor pulmonale, and right heart failure where afterload reduction on the right side may be desirable.
